EpiCast Report: Postherpetic Neuralgia - Epidemiology Forecast to 2022

LONDON - Nov. 14, 2013 - PRLog -- Due to the growth of the elderly population worldwide, the number of postherpetic neuralgia (PHN) incident cases in the seven major markets (7MM) will increase by 20.22% over the next decade, from 241,808 cases in 2012 to 290,684 in 2022, forecasts research and consulting firm GlobalData.

The company’s latest report* states that among the 7MM (US, France, Germany, Italy, Spain, UK and Japan), the US and France will have more than 50% of the total incident cases between them throughout the forecast period. Studies report that the incidence of PHN varies widely in Europe, from 2.6% of patients in the Netherlands, to 32.1% of patients in France.

Suman Morampudi, GlobalData’s Epidemiologist, says: “The strongest established risk factor for PHN is advancing age, occurring in people ages 60 years and older. Other possible risk factors include severity of acute herpes zoster pain, extent of rash, and duration of prodromal pain. Additionally, common comorbidities associated with PHN include insomnia, depression, and anxiety.”

Currently, there is no absolute preventative therapy for PHN. However, a vaccine is available to help prevent a herpes zoster infection. In turn, this vaccine contributes towards reducing the incidence of PHN to a certain extent, as this condition is the consequence of herpes zoster.

For Sample Pages, please click or add the below link to your browser:

http://store.globaldata.com/market-reports/pharmaceutical... (http://store.globaldata.com/market-reports/pharmaceutical...)

“Since up to 5% of herpes zoster patients have periodic infections, the vaccine should be recommended for people of all ages, including those with and without a history of the virus.

Additionally, herpes zoster vaccination programs targeting people over the age of 60 years would not only help decrease the incidence of herpes zoster infections, but would also reduce the burden imposed by recurring infections,” concludes the analyst.

This report provides an overview of the risk factors and global trends of postherpetic neuralgia in the seven major markets (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast (2012–2022) of the incident cases segmented by age and sex. This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.

ABOUT GLOBALDATA

GlobalData is the premier source of actionable insight into the energy and healthcare industries. With the combined expertise of more than 1,000 researchers, market analysts and consultants, we provide high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

For further details, please click or add the below link to your browser:

http://store.globaldata.com/market-reports/Pharmaceuticals-and-Healthcare/EpiCast-Report-Postherpetic-Neuralgia-Epidemiology-Forecast-to-2022#Report_Title&CompanyID=prlog (http://store.globaldata.com/market-reports/Pharmaceutical...)

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:pressreleases@globaldata.com


North America:          +1 646 395 5477

Europe:          +44 207 753 4299

         +44 1204 543 533

Asia Pacific:          +91 40 6616 6782